Search
forLearn
5 / 801 resultslearn Polyquaternium-10
learn heptyl glucoside
learn HYDROXYPROPYLAMMONIUM GLUCONATE
learn Hydrolyzed Quinoa
Research
5 / 1000+ resultsresearch Use of quaternized cassia galactomannan for hair conditioning.
Cassia HPTC is an effective hair conditioner, better than some traditional options.
research J. Cosmet. Sci., 158, 637–650 (November/December 2007) Use of quaternized cassia galactomannan for hair conditioning
Cassia HPTC is an effective hair conditioner, better than some traditional formulas.
research Recent Advances in Bioengineered Scaffolds for Cutaneous Wound Healing
Bioengineered scaffolds help heal skin wounds, but perfect treatments are still needed.
research Examining polyquaternium polymers deposition on human excised hair fibers
Certain polymers can stick to hair and increase volume, working best at a pH of 7 to 9.
research Cosmetics and Cosmeceutical Applications of Chitin, Chitosan and Their Derivatives
Chitin and chitosan are useful in cosmetics for oral care, haircare, and skincare, including UV protection and strength improvement.
Community Join
5 / 1000+ resultscommunity Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community Estimate of GT20029 on the grey market?
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.